On October 11, 2022 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting taking place in Boston from November 8-12, 2022 (Press release, Palleon Pharmaceuticals, OCT 11, 2022, View Source [SID1234621913]). E-602 Bi-Sialidase is a first-in-class, glyco-immune checkpoint inhibitor which restores anti-tumor immunity by enzymatically degrading immunosuppressive sialoglycans in hypersialylated tumors and immune cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Trials-in-Progress poster will include the specifics of the GLIMMER-01 trial (NCT#05259696) which is designed to assess the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602. The first patient was dosed in March of this year.

Details of the poster presentation are as follows:

Presentation Type: Poster Presentation (Abstract: #772)
Title: A Phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
Session: Poster Hall Session
Timing: November 11, 2022, 9:00 a.m. – 8:30 p.m. EST
Location: Hall C

The poster will appear on Palleon Pharmaceuticals’ website following the presentation.